Peter Lee

Dr. Peter Lee

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
PLPeter Lee
Peter Lee
KCKen Chin
Ken Chin
DLDanny Liew
Danny Liew
DSDion Stub
Dion Stub
ABAngela L Brennan
Angela L Brennan
EZElla Zomer
Ella Zomer
Objectives The objective of this systematic review was to examine the existing evidence base for the cost-effectiveness or cost-benefit of clinical quality registries (CQRs). Design Systematic review and narrative synthesis. Data sources Nine electronic bibliographic databases, including MEDLINE, EMBASE and CENTRAL, in the period from January 2000 to August 2019. Eligibility criteria Any peer-reviewed published study or grey literature in English which had reported on an economic evaluation of one or more CQRs. Data extraction and synthesis Data were screened, extracted and appraised by two independent reviewers. A narrative synthesis was performed around key attributes of each CQR and on key patient outcomes or changes to healthcare processes or utilisation. A narrative synthesis of the cost-effectiveness associated with CQRs was also conducted. The primary outcome was cost-effectiveness, in terms of the estimated incremental cost-effectiveness ratio (ICER), cost savings or return-on-investment (ROI) attributed to CQR implementation. Results Three studies and one government report met the inclusion criteria for the review. A study of the National Surgical Quality Improvement Programme (NSQIP) in the USA found that the cost-effectiveness of this registry improved over time, based on an ICER of US$8312 per postoperative event avoided. A separate study in Canada estimated the ROI to be US$3.43 per US$1.00 invested in the NSQIP. An evaluation of a post-splenectomy CQR in Australia estimated that registry cost-effectiveness improved from US$234 329 to US$18 358 per life year gained when considering the benefits accrued over the lifetime of the population. The government report evaluating five Australian CQRs estimated an overall return of 1.6–5.5 times the cost of investment. Conclusions Available data indicate that CQRs can be cost-effective and can lead to significant returns on investment. It is clear that further studies that evaluate the economic and clinical impacts of CQRs are necessary. PROSPERO registration number CRD42018116807.

27 January 2024 in Value in Health
Verified
Journal Article
Open access
PLPeter Lee
Peter Lee
LELidia Engel
Lidia Engel
ELErica Lubetkin
Erica Lubetkin
LGLan Gao
Lan Gao
The EQ Health and Wellbeing (EQ-HWB) is a novel measure which conceptually overlaps with the five-level EQ-5D (EQ-5D-5L) while capturing broader dimensions of health and wellbeing. This study aims to explore the extent to which the EQ-HWB and EQ-5D-5L capture overlapping or complementary constructs, as well as to explore the discriminative ability of the short-form EQ-HWB (EQ-HWB-S) as a multi-attribute utility instrument (MAUI) in the Australian setting. A secondary analysis of data from a nationally-representative cross-sectional survey of 2,002 Australian adults was performed. The survey included socioeconomic questions and health characteristics, as well as the EQ-HWB and EQ-5D-5L instruments. Convergent and known-group validity were evaluated through Spearman rank correlation and multivariable regression analyses, respectively. An exploratory factor analysis (EFA) was also performed to explore the underlying constructs of the two measures. Correlation coefficients varied from moderate to strong (rs ≥ 0.40) between the EQ-5D-5L and the corresponding EQ-HWB dimensions (all P<0.001). Based on the EFA, both instruments measure similar underlying constructs, with the EQ-HWB capturing broader aspects of wellbeing. The known-group analysis demonstrated the relative discriminative ability of the EQ-HWB-S in capturing broader aspects of health and wellbeing. The EQ-HWB was at least moderately correlated with the EQ-5D-5L in overlapping domains/dimensions and demonstrated greater sensitivity in participants with mental health problems versus the EQ-5D-5L. Our findings support future research exploring the value of the EQ-HWB-S as a MAUI for the general Australian population.

7 December 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
PLPeter Lee
Peter Lee
ABAngela L Brennan
Angela L Brennan
DSDion Stub
Dion Stub
DDDiem T Dinh
Diem T Dinh
JLJeffrey Lefkovits
Jeffrey Lefkovits
DLDanny Liew
Danny Liew
Objectives In this study, we sought to evaluate the costs of percutaneous coronary intervention (PCI) across a variety of indications in Victoria, Australia, using a direct per-person approach, as well as to identify key cost drivers. Design A cost-burden study of PCI in Victoria was conducted from the Australian healthcare system perspective. Setting A linked dataset of patients admitted to public hospitals for PCI in Victoria was drawn from the Victorian Cardiac Outcomes Registry (VCOR) and the Victorian Admitted Episodes Dataset. Generalised linear regression modelling was used to evaluate key cost drivers. From 2014 to 2017, 20 345 consecutive PCIs undertaken in Victorian public hospitals were captured in VCOR. Primary outcome measures Direct healthcare costs attributed to PCI, estimated using a casemix funding method. Results Key cost drivers identified in the cost model included procedural complexity, patient length of stay and vascular access site. Although the total procedural cost increased from $A55 569 740 in 2014 to $A72 179 656 in 2017, mean procedural costs remained stable over time ($A12 521 in 2014 to $A12 185 in 2017) after adjustment for confounding factors. Mean procedural costs were also stable across patient indications for PCI ($A9872 for unstable angina to $A15 930 for ST-elevation myocardial infarction) after adjustment for confounding factors. Conclusions The overall cost burden attributed to PCIs in Victoria is rising over time. However, despite increasing procedural complexity, mean procedural costs remained stable over time which may be, in part, attributed to changes in clinical practice.

3 October 2024 in Social Science & Medicine
Verified
Journal Article
Open access
NDNeha Das
Neha Das
IMIshani K. Majumdar
Ishani K. Majumdar
PAPaul A. Agius
Paul A. Agius
PLPeter Lee
Peter Lee
SRSuzanne Robinson
Suzanne Robinson
LGLan Gao
Lan Gao
Productivity-adjusted life-year (PALY) is a relatively new measure for quantifying the impact of disease on productivity. This study aims to systematically review the productivity factors such as absenteeism and presenteeism among informal caregivers of patients with a wide range of chronic health conditions to inform the PALY quantifications. A literature search across MEDLINE, Embase, EconLIT, PsychInfo, and CINAHL identified 3578 studies from which a final 23 studies were included in the analysis. To explore the pooled estimate of caregiver absenteeism/presenteeism across diseases and possible drivers, a meta-analysis and meta-regression were conducted using studies where relevant data was available. The pooled proportion for absenteeism, presenteeism, and work productivity loss (WPL) was 14% (95% Confidence Interval [CI]:9-19%; I2 = 96.3%), 32% (95% CI:22-42%; I2 = 98.0%) and 44% (95% CI:35-53%; I2 = 95.4%) respectively with a high a level of heterogeneity. Factors such as the disease type, and disease severity can influence the caregivers' work productivity. The data derived in this study will enable the derivation of productivity indices to estimate PALY among caregivers. Future studies can explore the work productivity impact among caregivers of patients with other chronic conditions where they have a significant role but are unexplored, and severity-wise studies in conditions such as stroke and dementia to understand the caregivers' societal productivity impact.

10 November 2022 in Journal of Occupational Rehabilitation
Verified
Journal Article
Open access
PDF file
PLPeter Lee
Peter Lee
TXTing Xia
Ting Xia
EZElla Zomer
Ella Zomer
CVCaryn van Vreden
Caryn van Vreden
EPElizabeth Pritchard
Elizabeth Pritchard
ZAZanfina Ademi
Zanfina Ademi
Background The transport and logistics industry contributes to a significant proportion of the Australian economy. However, few studies have explored the economic and clinical burden attributed to poor truck driver health. We therefore estimated the work-related mortality burden among truck drivers over a 10-year period. Methods Dynamic life table modelling was used to simulate the follow-up of the Australian male working-age population (aged 15–65 years) over a 10-year period of follow-up (2021–2030). The model estimated the number of deaths occurring among the Australian working population, as well as deaths occurring for male truck drivers. Data from the Driving Health study and other published sources were used to inform work-related mortality and associated productivity loss, hospitalisations and medication costs, patient utilities and the value of statistical life year (VoSLY). All outcomes were discounted by 5% per annum. Results Over 10 years, poor truck driver health was associated with a loss of 21,173 years of life lived (discounted), or 18,294 QALYs (discounted). Healthcare costs amounted to AU$485 million (discounted) over this period. From a broader, societal perspective, a total cost of AU$2.6 billion (discounted) in lost productivity and AU$4.7 billion in lost years of life was estimated over a 10-year period. Scenario analyses supported the robustness of our findings. Conclusions The health and economic consequences of poor driver health are significant, and highlight the need for interventions to reduce the burden of work-related injury or disease for truck drivers and other transport workers.

22 February 2022 in Clinical Cardiology
Verified
Journal Article
Open access
PLPeter Lee
Peter Lee
ABAngela Brennan
Angela Brennan
DDDiem Dinh
Diem Dinh
DSDion Stub
Dion Stub
JLJeffrey Lefkovits
Jeffrey Lefkovits
DLDanny Liew
Danny Liew
Background: Despite evidence of the comparative benefits of transradial access percutaneous coronary intervention (PCI) over transfemoral access, its uptake remains highly varied across Australia. Few studies have explored the implications of the choice of access site during PCI from the perspective of the Australian healthcare setting. We, therefore, performed a cost‐effectiveness analysis of radial versus femoral access PCI.Methods: Data from the Victorian Cardiac Outcomes Registry (VCOR) were used to inform our economic analyses. Patients treated through either radial or femoral access PCI were propensity score‐matched using the inverse probability weighted (IPW) method, and the incidence of major bleeding and all‐cause mortality in the cohort was used to inform an economic model comprising a hypothetical sample of 1000 patients. Costs and utility data were drawn from published sources. The economic evaluation adopted the perspective of the Australian healthcare system.Results: Among a cohort of 1000 patients over 1 year, there were 19 fewer deaths, and six fewer episodes of nonfatal major bleeding in the radial group compared to the femoral group. Total cost savings attributed to radial access was AUD $1 214 688. Hence, from a health economic point of view, radial access PCI was dominant over femoral access PCI. Sensitivity analyses supported the robustness of these findings.Conclusions: Radial access is associated with improved patient outcomes and considerably lower costs relative to femoral access PCI. Our findings support radial access being the preferred approach for PCI across a variety of indications in Australia.